初次活检阴性且多参数磁共振成像阳性(前列腺影像报告和数据系统/利克特3-5)患者重复活检的前列腺癌检出百分比:一项小型系统综述
本系统综述纳入9项研究共485例患者,评估初次MRI靶向活检阴性但mpMRI阳性(PI-RADS/Likert 3-5)患者重复活检的前列腺癌检出率。PI-RADS 3病灶总体和临床显著前列腺癌检出百分比分别为0%-80%和0%-20%,PI-RADS≥4病灶分别为15.4%-86%和7.7%-57%。作者建议对此类患者重新阅片并随访重复mpMRI或对最高风险者行标准重复活检。
要点
- 初次MRI靶向活检阴性但mpMRI阳性者重复活检仍可检出前列腺癌。
- PI-RADS 3病灶总体癌检出百分比0%-80%,临床显著癌0%-20%。
- PI-RADS≥4病灶总体癌检出百分比15.4%-86%,临床显著癌7.7%-57%。
核心结论
- 在MRI阳性且初次MRI靶向活检阴性的患者中,作者建议重新阅片并随访重复mpMRI或对最高风险者行标准重复活检。
研究设计与样本
- 系统综述,检索1179篇文献后纳入9项研究,共485例患者。
- 纳入患者为初次MRI靶向前列腺活检组织学阴性但此前mpMRI显示PI-RADS/Likert 3-5病灶者。
主要发现
- PI-RADS 3病灶患者总体前列腺癌检出百分比为0%-80%,临床显著前列腺癌为0%-20%。
- PI-RADS≥4病灶患者总体前列腺癌检出百分比为15.4%-86%,临床显著前列腺癌为7.7%-57%。
- Likert 5病灶患者报告的总体癌检出百分比为87.5%。
关键数值与推荐
- 临床显著前列腺癌定义为国际泌尿病理学会分级>1或任何已提供的定义。
临床怎么用
- 作者建议对MRI阳性且初次MRI靶向活检阴性的患者重新阅片,并随访重复mpMRI或对最高风险者行标准重复活检。
局限性
- 本综述的局限性是研究数量少以及方案修订允许纳入患者数<50的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiparametric magnetic resonance imaging (mpMRI) has high sensitivity but low specificity for prostate cancer (PCa) diagnosis. The aim of our systematic review was to investigate the proportion of PCa found at a repeat biopsy in patients with a negative initial prostate biopsy, despite initial positive mpMRI. Included patients had a Prostate Imaging Reporting and Data System (PI-RADS)/Likert 3-5 lesion on mpMRI prior to the initial mpMRI-targeted prostate biopsy, which was negative for PCa on histology. The main outcomes were the overall and clinically significant PCa (csPCa; International Society of Urological Pathology >1 or any provided definition) percentages at a repeat biopsy. Out of 1179 articles identified, nine studies were included (a total of 485 patients). For patients with PI-RADS 3 lesions, overall and csPCa detection percentages ranged from 0% to 80% and from 0% to 20%, respectively, while for patients with PI-RADS ≥4 lesions, the corresponding percentages were 15.4-86% and 7.7-57%. An overall cancer detection percentage of 87.5% was reported in patients with Likert 5 lesions. Limitation of our review is the small number of studies and the protocol revision that allowed studies with <50 patients. In patients with a positive MRI result and a negative initial MRI-targeted biopsy, we suggest MRI re-reading and follow-up with repeat mpMRI or the standard repeat biopsy in cases at the highest risk. PATIENT SUMMARY: Literature has shown that in men with an abnormal prostate magnetic resonance imaging (MRI) scan but a normal biopsy, a significant prostate cancer can be present. MRI scans should be double checked, followed by standard checkups or repeat prostate biopsy, especially in highly suspicious cases.
引用
- Grivas N, Lardas M, Espinós EL, et al. Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System/Likert 3-5) and Negative Initial Biopsy. A Mini Systematic Review. Eur Urol. 2022. PMID: 35985901. doi:10.1016/j.eururo.2022.07.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。